2022 January 11;12:820006.” In this review article, the authors discussed the role of the calcitonin gene-related peptide (CGRP) pathway in gastrointestinal (GI) physiology, with a specific focus on constipation associated with the use of CGRP pathway–targeted treatments for the prevention of migraine [the monoclonal antibody (mAb) against the CGRP receptor (erenumab); mAbs against the CGRP ligand (fremanezumab, galcanezumab)] and for the acute treatment of migraine [small molecule CGRP receptor antagonists (ubrogepant)] (Holzer and Holzer-Petsche, 2022). This evidence concerns the gene CALCA and migraine disorder.